Cognito Therapeutics today announced new study results showing that its Spectris AD therapy significantly slows Alzheimer's ...

Cognito Forms is a game-changer, automating administrative work and streamlining business processes. Its powerful data collection and user-friendly interface empower global innovators. With both ...

Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for ...

But startup Cognito Therapeutics is taking a drug-free approach to treating the memory-robbing disease. The Cambridge, Massachusetts–based company is developing a headset to combat cognitive ...

One startup is testing whether a "disco" of light and sound can slow the disease in patients. Cognito Therapeutics raised $73 million to test this theory in hundreds of people. For decades ...

(Cognito Therapeutics) The Hope study will task upwards of 400 people with mild to moderate Alzheimer’s with using the noninvasive device at home every day for 12 months, throughout which they ...

- Data will highlight durability of treatment effect and significant impact on slowing disease progression. - No treatment-related serious adverse events (SAEs) or incidents of amyloid-related ...

Dr. Rick Kuntz, former Senior Vice President, Chief Medical and Scientific Officer at Medtronic, joins Cognito Board of Directors. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics ...

The series B round adds $73 million to Cognito’s coffers, the startup announced Wednesday. It’ll go toward the ongoing pivotal study of the noninvasive headset, which relies on light waves and ...

Cognito Therapeutics has raised $50 million in funding as it seeks to advance treatments for an elusive target: cognitive decline. Cognito, based in Cambridge, Mass., is developing a headset that ...